News - Selux Diagnostics

In the News

FDA Clears ‘Selux NGP System’ for Rapid Antibiotic Susceptibility Testing

January 19, 2023

Dr. James S. Lewis II, Antibiotic Susceptibility Test Expert, Joins as Chair of Selux Diagnostics’ Clinical Advisory Board

October 18, 2022

Science is a Puzzle: Selux Diagnostics Director of Research and Development Kelly Flentie On Collaboration, Idea Diversity, and Solving One of the Biggest Medical Problems of Our Time

April 26, 2022

Selux Diagnostics pulls in $50m Series C

March 3, 2022

Selux secures $50M for commercialization of antimicrobial susceptibility testing platform

March 3, 2022

Selux Diagnostics Announces Additional $50 Million in Series C Funding

February 28, 2022

Selux Diagnostics Eyes First Half of 2022 for Next-Gen AST Platform Launch

November 16, 2021

Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial Officer

November 16, 2021

Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP Platform

October 19, 2021

Breakthrough device designation for AST platform

October 4, 2021

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform

September 28, 2021

Selux wins FDA breakthrough device designation for phenotyping platform

September 28, 2021

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid Samples

September 28, 2021

Health Tech: Aleksandar Vacic On How Selux Diagnostics’s Technology Can Make An Important Impact In Our Overall Wellness

August 19, 2021

BARDA grants additional funding for rapid antibiotic susceptibility test

June 14, 2021